Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients

MLA

Howard S. Roth, et al. “Synergistic and Targeted Therapy with a Procaspase-3 Activator and Temozolomide Extends Survival in Glioma Rodent Models and Is Feasible for the Treatment of Canine Malignant Glioma Patients.” Oncotarget, vol. 8, July 2017, pp. 80124–38. EBSCOhost, https://doi.org/10.18632/oncotarget.19085.

APA

Howard S. Roth, Antonella Mangraviti, Lisa J. Schlein, Timothy M. Fan, Gregory J. Riggins, Michael Podell, Alexandra Borodovsky, Jayme Looper, Rachel C. Botham, Betty Tyler, Paul J. Hergenrother, Avadhut D. Joshi, & Steve Joslyn. (2017). Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget, 8, 80124–80138. https://doi.org/10.18632/oncotarget.19085

Chicago

Howard S. Roth, Antonella Mangraviti, Lisa J. Schlein, Timothy M. Fan, Gregory J. Riggins, Michael Podell, Alexandra Borodovsky, et al. 2017. “Synergistic and Targeted Therapy with a Procaspase-3 Activator and Temozolomide Extends Survival in Glioma Rodent Models and Is Feasible for the Treatment of Canine Malignant Glioma Patients.” Oncotarget 8 (July): 80124–38. doi:10.18632/oncotarget.19085.